Hypothyroidism. Hypothyroidism, unspecified
Conditions
Interventions
Intervention 1: Intervention group: A daily dose of 500 mg of FimiLact synbiotic capsule was read 2 hours after Levothyroxine tablet for 8 weeks (dosage of 1 capsule per day). Synthetic FamiLact Synth
Sponsors
Esfahan University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: Age of 18 to 65 years Hypothyroid patients with a history of treatment for more than one year using levothyroxine (sodium) TSH is at least one year with a constant dose of levothyroxine in the normal range No smoking and alcohol Non pregnant, non-lactating Non-use of drugs that affect metabolism and absorption of levothyroxine include: iron sulfate, magnesium sulfate, warfarin, luvastatin, amiodarone, sumatropin, calcium carbonate, orlistat, multivitamin and minerals, theophylline, ritunavir, rifampin, phenytoin, karmazapine, Phenobarbital, Sucralfate, Aluminum hydroxide, Sertraline, Bile doses, Estrogens and other estrogen modifying drugs, Proton pump suppressants, Phosphate binders People who, after explaining the work, were willing to cooperate and answer questions and conduct experiments
Exclusion criteria
Exclusion criteria: Thyroid cancer Intestinal malabsorption (history of obstructive surgery, inflammatory bowel disease, celiac disease) Antibiotic use Acute and chronic infectious diseases Use of drugs that affect the absorption and metabolism of levothyroxine, including (iron sulfate, magnesium sulfate, warfarin, luvastatin, amiodarone, sumatropin, calcium carbonate, orlistat, multivitaminomineral, theophylline, ritunavir, rifampin, Tween, Karmazpine, Phenobarbital, Sucralfate, Aluminum Hydroxide, Sertraline, Bile Drug, Estrogen and other estrogen modifying drugs, proton pump inhibitor drugs, phosphate binders)
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Thyroid-stimulating hormone. Timepoint: Before the start of the study and 8 weeks after the intervention. Method of measurement: enzyme-linked immunosorbent assay (ELISA).;Free triiodothyronine (FT3). Timepoint: Before the start of the study and 8 weeks after the intervention. Method of measurement: enzyme-linked immunosorbent assay (ELISA). | — |
Secondary
| Measure | Time frame |
|---|---|
| Anti-thyroid peroxidase. Timepoint: Before intervention and 8 weeks after intervention. Method of measurement: enzyme-linked immunosorbent assay (ELISA).;C-reactive protein. Timepoint: Before intervention and 8 weeks after intervention. Method of measurement: Laboratory analysis.;Weight. Timepoint: Before intervention and 8 weeks after intervention. Method of measurement: Digital scale.;Waist Circumference. Timepoint: Before intervention and 8 weeks after intervention. Method of measurement: non-stretching tape measure.;Waist / hip ratio - WHR. Timepoint: Before intervention and 8 weeks after intervention. Method of measurement: non-stretching tape measure.;Systolic blood pressure. Timepoint: Before intervention and 8 weeks after intervention. Method of measurement: Sphygmomonometer.;Diastolic blood pressure. Timepoint: Before intervention and 8 weeks after intervention. Method of measurement: Sphygmomonometer.;Body Mass Index. Timepoint: Before intervention and 8 weeks after intervention. Method of measurement: Dividing the weight into kilograms by squared height by meter.;Depression score. Timepoint: Before intervention and 8 weeks after intervention. Method of measurement: Depression Anxiety and Stress Scales (DASS-21).;Anxiety score. Timepoint: Before intervention and 8 weeks after intervention. Method of measurement: Depression Anxiety and Stress Scales (DASS-21).;Stress score. Timepoint: Before intervention and 8 weeks after intervention. Method of measurement: Depression Anxiety and Stress Scales (DASS-21).;Appetite. Timepoint: Before intervention and 8 weeks after intervention. Method of measurement: Visual Analogue Scale.;Multidimensional Fatigue Inventory. Timepoint: Before intervention and 8 weeks after intervention. Method of measurement: multidimensional fatigue inventory (MFI-20).;Fatigue Intensity. Timepoint: Before intervention and 8 weeks after intervention. Method of measurement: Fatigue severity scale (FSS).;Quality of Life. Timepoint: Before inte | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactGholamreza Askari
Esfahan University of Medical Sciences
Outcome results
None listed